Skip to main content

GERD Symptoms in the General Population: Prevalence and Severity Versus Care-Seeking Patients

Abstract

Background

Prior estimates suggest that up to 40 % of the US general population (GP) report symptoms of gastroesophageal reflux disease (GERD). However, symptoms in the GP versus patients seeking care for gastrointestinal (GI) complaints have not been compared. We estimated the prevalence and severity of GERD symptoms in the GP versus GI patients, and identified predictors of GERD severity. We hypothesized that similar to functional GI disorders, psychosocial factors would predict symptom severity in GERD as much, or perhaps more, than care-seeking behavior alone.

Methods

We compared the prevalence of heartburn and regurgitation between a sample from the US GP and patients seeking GI specialty care. We compared GERD severity between groups using the NIH PROMIS® GERD scale. We then performed multivariable regression to identify predictors of GERD severity.

Results

There was no difference in the prevalence of heartburn between the GP and patient groups (59 vs. 59 %), but regurgitation was more common in patients versus GP (46 vs. 39 %; p = 0.004). In multivariable regression, having high visceral anxiety (p < 0.001) and being divorced or separated (p = 0.006) were associated with higher GERD severity.

Conclusions

More than half of a GP sample reports heartburn—higher than previous series and no different from GI patients. Although regurgitation was more prevalent in patients versus the GP, there was no difference in GERD severity between groups after adjusting for other factors; care seeking in GERD appears related to factors beyond symptoms, including visceral anxiety.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

Abbreviations

GI:

Gastrointestinal

PRO:

Patient-reported outcome

HRQOL:

Health-related quality of life

PROMIS:

Patient-Reported Outcome Measurement Information System

References

  1. 1.

    Tack J, Becher A, Mulligan C, et al. Systematic review: the burden of disruptive gastro-oesophageal reflux disease on health-related quality of life. Aliment Pharmacol Ther. 2012;35:1257–1266.

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Becher A, El-Serag H. Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2011;34:618–627.

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007;5:17–26.

    PubMed  Article  Google Scholar 

  4. 4.

    A Gallup survey on heartburn across America. Princeton, NJ: The Gallup Organization, Inc., 1988.

  5. 5.

    Agreus L, Svardsudd K, Talley NJ, et al. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol. 2001;96:2905–2914.

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Fedorak RN, Veldhuyzen van Zanten S, Bridges R. Canadian Digestive Health Foundation public impact series: gastroesophageal reflux disease in Canada: incidence, prevalence, and direct and indirect economic impact. Can J Gastroenterol. 2010;24:431–434.

    PubMed  PubMed Central  Google Scholar 

  7. 7.

    Frank L, Kleinman L, Ganoczy D, et al. Upper gastrointestinal symptoms in North America: prevalence and relationship to healthcare utilization and quality of life. Dig Dis Sci. 2000;45:809–818.

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710–717.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  9. 9.

    Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143:1179e1-3–1187e1-3.

    Article  Google Scholar 

  10. 10.

    Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol. 2005;3:543–552.

    PubMed  Article  Google Scholar 

  11. 11.

    Locke GR 3rd, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448–1456.

    PubMed  Article  Google Scholar 

  12. 12.

    El-Serag H, Hill C, Jones R. Systematic review: the epidemiology of gastro-oesophageal reflux disease in primary care, using the UK General Practice Research Database. Aliment Pharmacol Ther. 2009;29:470–480.

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Bretagne JF, Honnorat C, Richard-Molard B, et al. Comparative study of characteristics and disease management between subjects with frequent and occasional gastro-oesophageal reflux symptoms. Aliment Pharmacol Ther. 2006;23:607–616.

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Solmaz M, Kavuk I, Sayar K. Psychological factors in the irritable bowel syndrome. Eur J Med Res. 2003;8:549–556.

    PubMed  CAS  Google Scholar 

  15. 15.

    Van Oudenhove L, Aziz Q. The role of psychosocial factors and psychiatric disorders in functional dyspepsia. Nat Rev Gastroenterol Hepatol. 2013;10:158–167.

    PubMed  Article  Google Scholar 

  16. 16.

    Cella D, Yount S, Rothrock N, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care. 2007;45:S3–S11.

    PubMed  Article  PubMed Central  Google Scholar 

  17. 17.

    Spiegel BM. Patient-reported outcomes in gastroenterology: clinical and research applications. J Neurogastroenterol Motil. 2013;19:137–148.

    PubMed  Article  PubMed Central  Google Scholar 

  18. 18.

    Spiegel B, Hays RD, Bolus R, et al. Development of the NIH Patient Reported Outcomes Measurement Information System (PROMIS®) Gastrointestinal Symptom Scales. Am J Gastroenterol. 2014 (in press).

  19. 19.

    Labus JS, Bolus R, Chang L, et al. The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale. Aliment Pharmacol Ther. 2004;20:89–97.

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Labus JS, Mayer EA, Chang L, et al. The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. Psychosom Med. 2007;69:89–98.

    PubMed  Article  Google Scholar 

  21. 21.

    Revicki DA, Wood M, Wiklund I, et al. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res. 1998;7:75–83.

    PubMed  Article  CAS  Google Scholar 

  22. 22.

    DeWalt DA, Rothrock N, Yount S, et al. Evaluation of item candidates: the PROMIS qualitative item review. Med Care. 2007;45:S12–S21.

    PubMed  Article  PubMed Central  Google Scholar 

  23. 23.

    Spiegel B, Khanna D, Bolus R, et al. Understanding gastrointestinal distress: a framework for clinical practice. Am J Gastroenterol. 2011;106:380–385.

  24. 24.

    Baker LH, Lieberman D, Oehlke M. Psychological distress in patients with gastroesophageal reflux disease. Am J Gastroenterol. 1995;90:1797–1803.

    PubMed  CAS  Google Scholar 

  25. 25.

    Wong RK, Drossman DA, Weinland SR, et al. Partner burden in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11:151–155.

    PubMed  Article  Google Scholar 

  26. 26.

    Spiegel BM. Burden of illness in irritable bowel syndrome: looking beyond the patient. Clin Gastroenterol Hepatol. 2013;11:156–157.

    PubMed  Article  Google Scholar 

  27. 27.

    Naliboff BD, Mayer M, Fass R, et al. The effect of life stress on symptoms of heartburn. Psychosom Med. 2004;66:426–434.

    PubMed  Article  Google Scholar 

  28. 28.

    Delaney B. Prevalence and epidemiology of gastro-esophageal reflux disease. Aliment Pharmacol Ther. 2004;20:2–4.

    PubMed  Article  Google Scholar 

  29. 29.

    Talley NJ, Zinsmeister AR, Schleck CD, et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology. 1992;102:1259–1268.

    PubMed  CAS  Google Scholar 

  30. 30.

    El-Serag HB, Petersen NJ, Carter J, et al. Gastroesophageal reflux among different racial groups in the United States. Gastroenterology. 2004;126:1692–1699.

    PubMed  Article  Google Scholar 

  31. 31.

    Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146.

    PubMed  Article  Google Scholar 

  32. 32.

    van Soest EM, Dieleman JP, Siersema PD, et al. Increasing incidence of Barrett’s oesophagus in the general population. Gut. 2005;54:1062–1066.

    PubMed  Article  PubMed Central  Google Scholar 

  33. 33.

    Locke GR, 3rd, Talley NJ, Fett SL, et al. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med. 1999;106:642–649.

Download references

Acknowledgments

NIH/NIAMS U01 AR057936A, the National Institutes of Health through the NIH Roadmap for Medical Research Grant (AR052177). Puja Khanna was supported by Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant NIAMS 1 T32 AR053463 and ACR Research and Education Foundation Clinical Investigator Fellowship Award 2009_11. Dinesh Khanna was also supported by NIAMS K24 AR063120. Ron Hays was also supported by NIH/NIA Grants P30-AG028748 and P30-AG021684, and NCMHD Grant 2P20MD000182. Lin Chang was also supported by NIDDK P50 DK64539.

Conflict of interest

Brennan Spiegel has received grant support from Ironwood, Amgen, and Shire Pharmaceuticals, and served as a consultant to Ironwood, Forest, and Takeda North America. Dinesh Khanna has served as consultant and/or received grant support from Actelion, Astra-Zeneca, Bayer, BMS, DIGNA, Genentech, Gilead, InterMune, Merck, Takeda, Savient, and United Therapeutics. Ron D. Hays has served as a consultant to Amgen, Allergan, Pfizer, and the Critical Path Institute. Gil Melmed has served as a consultant for Abbvie and Jannsen, is on the speaker’s bureau for Prometheus and Abbott, and has received research support from Pfizer. Lin Chang has served as a consultant to Ironwood, Forest, Prometheus, Salix, Takeda North America and has received grant support from Shire and Ironwood.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Brennan Spiegel.

Additional information

Disclaimer The opinions and assertions contained herein are the sole views of the authors and are not to be construed as official or as reflecting the views of the Department of Veteran Affairs.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cohen, E., Bolus, R., Khanna, D. et al. GERD Symptoms in the General Population: Prevalence and Severity Versus Care-Seeking Patients. Dig Dis Sci 59, 2488–2496 (2014). https://doi.org/10.1007/s10620-014-3181-8

Download citation

Keywords

  • Gastroesophageal reflux disease
  • Patient-reported outcomes
  • Symptoms